![New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation - ScienceDirect New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0045206820302984-ga1.jpg)
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation - ScienceDirect
![Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing - ScienceDirect Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523421006279-gr1.jpg)
Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing - ScienceDirect
![Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia | Leukemia Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-019-0659-6/MediaObjects/41375_2019_659_Fig1_HTML.png)
Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia | Leukemia
![New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation - ScienceDirect New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0045206820302984-gr1.jpg)
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation - ScienceDirect
![Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology | ACS Pharmacology & Translational Science Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology | ACS Pharmacology & Translational Science](https://pubs.acs.org/cms/10.1021/acsptsci.1c00223/asset/images/large/pt1c00223_0004.jpeg)
Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology | ACS Pharmacology & Translational Science
![Frontiers | Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia | Oncology Frontiers | Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia | Oncology](https://www.frontiersin.org/files/Articles/378904/fonc-08-00255-HTML/image_m/fonc-08-00255-g001.jpg)
Frontiers | Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia | Oncology
![Histone lysine specific demethylase 1 inhibitors - RSC Medicinal Chemistry (RSC Publishing) DOI:10.1039/D0MD00141D Histone lysine specific demethylase 1 inhibitors - RSC Medicinal Chemistry (RSC Publishing) DOI:10.1039/D0MD00141D](https://pubs.rsc.org/image/article/2020/MD/d0md00141d/d0md00141d-f13_hi-res.gif)
Histone lysine specific demethylase 1 inhibitors - RSC Medicinal Chemistry (RSC Publishing) DOI:10.1039/D0MD00141D
![Frontiers | LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells | Oncology Frontiers | LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells | Oncology](https://www.frontiersin.org/files/Articles/472623/fonc-09-00721-HTML/image_m/fonc-09-00721-g001.jpg)
Frontiers | LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells | Oncology
Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition | Haematologica
![LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Journal of Hematology & Oncology | Full Text LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-019-0811-9/MediaObjects/13045_2019_811_Fig1_HTML.png)
LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Journal of Hematology & Oncology | Full Text
![LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Journal of Hematology & Oncology | Full Text LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-019-0811-9/MediaObjects/13045_2019_811_Fig3_HTML.png)
LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Journal of Hematology & Oncology | Full Text
![Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid–induced differentiation Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid–induced differentiation](https://www.science.org/cms/asset/fea72114-2c93-49e3-84ed-d7211be3a84f/aax2746-f1.gif)
Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid–induced differentiation
![LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma | EMBO Molecular Medicine LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/4f1f6156-bfa9-4f60-97d0-c44713112a55/emmm202012525-fig-0007-m.jpg)
LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma | EMBO Molecular Medicine
LSD1 as a Biomarker and the Outcome of Its Inhibitors in the Clinical Trial: The Therapy Opportunity in Tumor
![A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy | Leukemia A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-020-0892-z/MediaObjects/41375_2020_892_Fig1_HTML.png)